Rodman & Renshaw Begins Coverage on Eupraxia Pharmaceuticals (NASDAQ:EPRX)

Rodman & Renshaw started coverage on shares of Eupraxia Pharmaceuticals (NASDAQ:EPRX) in a report published on Thursday, Marketbeat reports. The firm issued a buy rating and a $9.00 price target on the stock.

Eupraxia Pharmaceuticals Stock Up 7.9 %

EPRX traded up $0.23 on Thursday, hitting $3.13. The company’s stock had a trading volume of 15,382 shares, compared to its average volume of 15,384. The company’s 50 day simple moving average is $2.66 and its 200-day simple moving average is $2.68. The firm has a market cap of $85.39 million and a P/E ratio of -4.08. Eupraxia Pharmaceuticals has a 12 month low of $2.20 and a 12 month high of $5.58.

Institutional Trading of Eupraxia Pharmaceuticals

A hedge fund recently bought a new stake in Eupraxia Pharmaceuticals stock. 180 Wealth Advisors LLC bought a new position in Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) during the second quarter, according to the company in its most recent filing with the SEC. The firm bought 13,000 shares of the company’s stock, valued at approximately $34,000.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company’s lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.